[Updated 2/22/19, 2:42 pm CT. See below.] Exact Sciences screened 934,000 patients for colorectal cancer in 2018 using its stool-based diagnostic test, Cologuard, resulting in a 71 percent surge in annual revenue to $454.5 million, the company announced Thursday.
Exact (NASDAQ: EXAS), which relocated from the Boston area to Madison, WI, in 2009, is one of the area’s fastest-growing healthcare companies and an increasingly prominent player in cancer diagnostics. It’s now valued at $10.5 billion. It employs more than 1,600 people, including 1,200 in the Madison area, the company said last August, when it broke ground on… Read more »
